Celularity and Fountain Life Launch Placental Cell Therapy Under Florida's New Regenerative Medicine Law
Event summary
- Celularity and Fountain Life announced the availability of cenplacel-L, a placental-derived investigational cell therapy, for investigational use by licensed physicians in Florida under new state legislation.
- Florida's new law, effective July 1, 2025, authorizes licensed physicians to perform certain cell therapies without FDA approval, provided they meet strict sourcing, manufacturing, and patient consent requirements.
- Celularity's cenplacel-L is a proprietary formulation with demonstrated immunomodulatory and regenerative potential, targeting inflammation, degeneration, and age-related diseases.
- The partnership with Fountain Life provides an initial clinical channel for implementation, integrating advanced diagnostics, patient selection, and physician oversight.
The big picture
This milestone marks the establishment of one of the first state-level frameworks in the United States enabling the physician-directed use of allogeneic cellular therapies outside of traditional federal approval pathways. Celularity is uniquely positioned to support this opportunity through its FDA-registered, GMP-compliant manufacturing infrastructure and existing inventory of clinical-grade product, enabling near-term clinical deployment. The partnership with Fountain Life underscores a broader industry trend towards integrating advanced diagnostics and AI-driven health intelligence into regenerative medicine.
What we're watching
- Regulatory Expansion
- Whether Florida's framework will serve as a model for broader adoption of regenerative therapies in other states.
- Clinical Adoption
- The pace at which licensed physicians in Florida will incorporate cenplacel-L into patient care.
- Market Dynamics
- How the availability of cenplacel-L under Florida law will impact Celularity's strategic positioning and potential market expansion.
Related topics